Literature DB >> 23398933

Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs.

Jacqueline Araújo Fiuza1, Helton da Costa Santiago, Angamuthu Selvapandiyan, Sreenivas Gannavaram, Natasha Delaqua Ricci, Lilian Lacerda Bueno, Daniella Castanheira Bartholomeu, Rodrigo Correa-Oliveira, Hira Lal Nakhasi, Ricardo Toshio Fujiwara.   

Abstract

Zoonotic visceral leishmaniasis, caused by the intracellular protozoan parasite Leishmania infantum, is a neglected tropical disease that is often fatal when untreated. Dogs are considered the main reservoir of L. infantum in zoonotic VL as the presence of infected dogs may increase the risk for human infection. Canine visceral leishmaniasis (CVL) is a major veterinary and public health problem in Southern Europe, Middle East and South America. Control of animal reservoirs relies on elimination of seropositive dogs in endemic areas. However, treatment of infected dogs is not considered a favorable approach as this can lead to emergence of drug resistance since the same drugs are used to treat human infections. Therefore, vaccination against CVL remains the best alternative in control of the animal reservoirs. In this study, we present data on the immunogenicity profile of a live attenuated parasite LdCen(-/-) in a canine infection model and compared it to that of Leishmune(®), a commercially available recombinant vaccine. The immunogenicity of the LdCen(-/-) parasites was evaluated by antibody secretion, production of intracytoplasmic and secreted cytokines, activation and proliferation of T cells. Vaccination with LdCen(-/-) resulted in high immunogenicity as revealed by the higher IgGTotal, IgG1, and IgG2 production and higher lymphoproliferative response. Further, LdCen(-/-) vaccinated dogs showed higher frequencies of activated CD4+ and CD8+ T cells, IFN-γ production by CD8+ T cells, increased secretion of TNF-α and IL-12/IL-23p40 and decreased secretion of IL-4. These results contribute to the understanding of immunogenicity elicited by live attenuated L. donovani parasites and, consequently, to the development of effective vaccines against visceral leishmaniasis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398933     DOI: 10.1016/j.vaccine.2013.01.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.

Authors:  Parna Bhattacharya; Ranadhir Dey; Pradeep K Dagur; Michael Kruhlak; Nevien Ismail; Alain Debrabant; Amritanshu B Joshi; Adovi Akue; Mark Kukuruga; Kazuyo Takeda; Angamuthu Selvapandiyan; John Philip McCoy; Hira L Nakhasi
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

Review 3.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

4.  Essential Role of Neutrophils in the Protective Immune Response Induced by a Live Attenuated Leishmania Vaccine.

Authors:  Parna Bhattacharya; Ranadhir Dey; Ankit Saxena; Subir Karmakar; Nevien Ismail; Sreenivas Gannavaram; Pradeep K Dagur; Monika Satoskar; Sanika Satoskar; Silvia De Paoli; Kazuyo Takeda; John Philip McCoy; Hira L Nakhasi
Journal:  J Immunol       Date:  2020-11-11       Impact factor: 5.422

Review 5.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

6.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

7.  LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Henrique Gama Ker; Nádia das Dores Moreira; Fernando Augusto Siqueira Mathias; Jamille Mirelle de Oliveira Cardoso; Nelder Figueiredo Gontijo; Oscar Bruna-Romero; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Parasit Vectors       Date:  2014-02-07       Impact factor: 3.876

Review 8.  Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.

Authors:  Sreenivas Gannavaram; Ranadhir Dey; Kumar Avishek; Angamuthu Selvapandiyan; Poonam Salotra; Hira L Nakhasi
Journal:  Front Immunol       Date:  2014-05-23       Impact factor: 7.561

Review 9.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

10.  A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured Trypanosoma cruzi strain, protecting against an in vivo virulent challenge.

Authors:  Fernando J Sánchez-Valdéz; Cecilia Pérez Brandán; Galia Ramírez; Alejandro D Uncos; M Paola Zago; Rubén O Cimino; Rubén M Cardozo; Jorge D Marco; Arturo Ferreira; Miguel Ángel Basombrío
Journal:  PLoS Negl Trop Dis       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.